Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy

Clinical Radiology

Volumn 67, Issue 5, 2012, Pages 429-436

  Kao, W Y ^a   Chiou, Y Y ^a,b   Hung, H H ^a,b   Su, C W ^a,b   Chou, Y H ^a,b   Wu, J C ^a,b   Huo, T I ^a,b   Huang, Y H ^a,b   Wu, W C ^a   Lin, H C ^a,b   Lee, S D ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CREATININE;

ADULT; AGED; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; REVIEW; RISK FACTOR; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME;

EID: 84859425495     PISSN: 00099260     EISSN: 1365229X     Source Type: Journal    
DOI: 10.1016/j.crad.2011.10.009     Document Type: Article

References (41)

1. M. Omata, L.A. Lesmana, and R. Tateishi Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma Hepatol Int 4 2010 439 474
2. H.H. Hung, C.W. Su, and C.R. Lai Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma Hepatol Int 4 2010 691 699
3. S.M. Lee, J.Y. Won, and D.Y. Lee Percutaneous cryoablation of small hepatocellular carcinomas using a 17-gauge ultrathin probe Clin Radiol 66 2011 752 759
4. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236 (Pubitemid 43112690)
5. J. Huang, L. Yan, and Z. Cheng A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria Ann Surg 252 2010 903 912
6. R. Lencioni Loco-regional treatment of hepatocellular carcinoma Hepatology 52 2010 762 773
7. G. Germani, M. Pleguezuelo, and K. Gurusamy Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis J Hepatol 52 2010 380 388
8. S.M. Lin, C.J. Lin, and C.C. Lin Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less Gut 54 2005 1151 1156
9. F. Brunello, A. Veltri, and P. Carucci Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial Scand J Gastroenterol 43 2008 727 735 (Pubitemid 351868714)
10. G. N'Kontchou, A. Mahamoudi, and M. Aout Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis Hepatology 50 2009 1475 1483
11. R. Tateishi, S. Shiina, and T. Teratani Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases Cancer 103 2005 1201 1209 (Pubitemid 40328091)
12. H.H. Hung, Y.Y. Chiou, and C.Y. Hsia Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas Clin Gastroenterol Hepatol 9 2011 79 86
13. H. Kim, H. Rhim, and D. Choi Recurrence and treatment pattern in long-term survivors with hepatocellular carcinoma: a comparison between radiofrequency ablation and surgery as a first-line treatment World J Surg 34 2010 1881 1886
14. W.Y. Kao, Y.Y. Chiou, and H.H. Hung Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index Eur J Gastroenterol Hepatol 23 2011 528 536
15. T. Livraghi, F. Meloni, and M. Di Stasi Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47 2008 82 89 (Pubitemid 351171044)
16. D. Choi, H.K. Lim, and H. Rhim Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series Eur Radiol 17 2007 684 692
17. J.C. Wu, Y.H. Huang, and G.Y. Chau Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma J Hepatol 51 2009 890 897
18. L.T. Chen, T.W. Liu, and Y. Chao Alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma Aliment Pharmacol Ther 22 2005 217 226 (Pubitemid 41153064)
19. S.L. Chan, F.K. Mo, and P.J. Johnson New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy J Clin Oncol 27 2009 446 452
20. Y.Y. Shao, Z.Z. Lin, and C. Hsu Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma Cancer 116 2010 4590 4596
21. A. Riaz, R.K. Ryu, and L.M. Kulik Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival J Clin Oncol 27 2009 5734 5742
22. M.C. Tsai, J.H. Wang, and C.H. Hung Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation J Gastroenterol Hepatol 25 2010 605 612
23. J. Bruix, M. Sherman, and J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430 (Pubitemid 32844200)
24. S.R. Vora, H. Zheng, and Z.K. Stadler Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma Oncologist 14 2009 717 725
25. K. Shirabe, K. Takenaka, and T. Gion Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection J Surg Oncol 64 1997 143 146 (Pubitemid 27106718)
26. M. Sherman The resurrection of alphafetoprotein J Hepatol 52 2010 939 940
27. R. Tateishi, S. Shiina, and H. Yoshida Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers Hepatology 44 2006 1518 1527 (Pubitemid 44953657)
28. Y.F. Liaw, D.I. Tai, and T.J. Chen Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma Liver 6 1986 133 137 (Pubitemid 17184758)
29. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
30. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
31. A. Riaz, K. Memon, and F.H. Miller Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation J Hepatol 54 2011 695 704
32. K. Yamamoto, H. Imamura, and Y. Matsuyama Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy Ann Surg Oncol 16 2009 2795 2804
33. A. Baldan, D. Marino, and M. Deg Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma Aliment Pharmacol Ther 24 2006 1495 1501 (Pubitemid 44657127)
34. M. Morimoto, K. Numata, and M. Kondou Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization Cancer 116 2011 5452 5460
35. V.W. Lam, K.K. Ng, and K.S. Chok Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors Ann Surg Oncol 15 2008 782 790
36. H. Kirikoshi, S. Saito, and M. Yoneda Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma Hepatol Res 39 2009 553 562
37. H. Fuke, K. Sugimoto, and K. Shiraki Predictive factors for distant recurrence of HCV-related hepatocellular carcinoma after radiofrequency ablation combined with chemoembolization Aliment Pharmacol Ther 27 2008 1253 1260 (Pubitemid 351697269)
38. A. Veltri, P. Moretto, and A. Doriguzzi Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC) Eur Radiol 16 2006 661 669 (Pubitemid 44149378)
39. R.R. Lopez Jr., S.H. Pan, and A.L. Hoffman Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma Arch Surg 137 2002 653 657
40. O. Seror, G. N'Kontchou, and M. Ibraheem Large (>or=5.0-cm) HCCs: multipolar RF ablation with three internally cooled bipolar electrodes - initial experience in 26 patients Radiology 248 2008 288 296
41. O. Barakat, R.P. Wood, and C.F. Ozaki Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis Liver Transpl 16 2010 289 299